Character Biosciences raises $93M with an eye on vision loss drugs
Character Biosciences, a biotech startup, has successfully raised $93 million in a Series B funding round to advance its vision loss treatments. The company plans to move two experimental drugs, CTX114 for geographic atrophy and CTX203 for intermediate age-related macular degeneration, into Phase 1 clinical trials this year. Character Biosciences aims to offer more effective solutions for dry AMD, a common form of vision loss, by leveraging a patient-first approach and extensive patient data.
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
Apellis Pharmaceuticals, Inc. announced eight oral presentations at the 49th Macula Society Annual Meeting, including new five-year data from the GALE extension study for SYFOVRE® (pegcetacoplan injection). These results highlight the benefits of early and continuous treatment with SYFOVRE in preserving retinal tissue and delaying disease progression in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The presentations reinforce SYFOVRE's position as a leading treatment for GA, backed by the largest data set with the longest follow-up for this condition.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Hold" from Analysts
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has received an average "Hold" recommendation from analysts, with a consensus 1-year price target of $33.00. Insider selling of 120,537 shares has occurred in the past 90 days, while institutional investors have shown mixed activity, with some increasing and others initiating positions. The company operates in the clinical-stage biopharmaceutical sector, focusing on novel therapies for rare and debilitating diseases.
Apellis announces eight oral presentations at the 49th Macula Society annual meeting
Apellis Pharmaceuticals will deliver eight oral presentations at the 49th Macula Society annual meeting, highlighting its commitment to advancing research in complement-mediated diseases. The company specializes in developing and commercializing therapeutic compounds, with approved treatments like SYFOVRE for geographic atrophy and EMPAVELI/Aspaveli for paroxysmal nocturnal hemoglobinuria (PNH). This news follows several recent analyst updates and S&P index additions for Apellis.
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
Apellis Pharmaceuticals, Inc. announced eight oral presentations for the 49th Macula Society Annual Meeting, including five-year results from the GALE extension study on its drug SYFOVRE. These results highlight the benefits of early and continuous treatment with SYFOVRE for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), showing meaningful impact on preserving retinal tissue and delaying disease progression. The company views these findings as crucial for patients living with GA, backing them with the largest GA dataset and longest follow-up to date.
Readystate Asset Management LP Takes Position in Apellis Pharmaceuticals, Inc. $APLS
Readystate Asset Management LP initiated a new position in Apellis Pharmaceuticals (NASDAQ:APLS) during Q3, acquiring 241,977 shares valued at approximately $5.48 million. This move represents 0.19% ownership for Readystate, while institutional ownership in Apellis is high at 96.29%. Company insiders, including CEO Cedric Francois, have been net sellers, contributing to a total of 120,537 shares sold by insiders worth about $2.61 million over the past 90 days, with insiders now holding 6.8% ownership.
Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline
Apellis Pharmaceuticals (APLS) is projected to report a year-over-year decline in Q4 2025 earnings and revenue, with an expected quarterly loss of $0.39 per share. The company currently has a negative Earnings ESP of -3.07% and a Zacks Rank #3, making it difficult to confidently predict an earnings beat. Investors are advised to consider other factors beyond just earnings expectations.
Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Tuesday
Apellis Pharmaceuticals (APLS) is slated to announce its Q4 2025 earnings before the market opens on Tuesday, February 24th, with analysts projecting a loss of ($0.41) per share and revenues around $199.3 million. Recent insider transactions show CEO Cedric Francois and CFO Timothy Sullivan sold shares, with insiders owning 6.8% of the company's stock. The stock has a "Hold" consensus rating from Wall Street with an average target price of $33.00, and institutional investors have significantly increased their positions.
Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline
Apellis Pharmaceuticals (APLS) is projected to report a year-over-year decline in Q4 earnings and lower revenues for the quarter ended December 2025. The company is expected to post a quarterly loss of $0.39 per share, with revenues estimated at $194.37 million. Despite a positive revision in the consensus EPS estimate over the last 30 days, the Earnings ESP of -3.07% and a Zacks Rank of #3 make it difficult to predict an earnings beat.
BofA upgrades Apellis (APLS) to buy citing rapid Empaveli adoption and underappreciated kidney disease market potential
Bank of America upgraded Apellis Pharmaceuticals (APLS) to a Buy rating, citing strong adoption of its drug Empaveli. The firm noted that the potential in the kidney disease market for Empaveli is currently underestimated by investors, which could drive future growth for Apellis.
Apellis Pharma chief business officer sells $8k in stock
Mark Jeffrey DeLong, Chief Business & Strategy Officer at Apellis Pharmaceuticals, sold 368 shares of common stock for $8,152 to cover tax withholding on Restricted Stock Units. After the transaction, he directly owns 114,591 shares. This news follows analyst rating adjustments for Apellis and its inclusion in market indices, alongside other recent company updates.
ING Groep NV Acquires 866,200 Shares of Apellis Pharmaceuticals, Inc. $APLS
ING Groep NV significantly increased its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 281.0%, acquiring an additional 866,200 shares to own a total of 1,174,500 shares valued at approximately $26.58 million. This acquisition makes ING Groep NV hold about 0.93% of the company, part of the 96.29% ownership by hedge funds and institutional investors. The article also notes mixed analyst ratings, recent target price cuts, and insider selling activity totaling $2.7 million over the past 90 days.
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced it will host a conference call and webcast on Tuesday, February 24, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results. Interested parties can pre-register for the call or access the live audio webcast and accompanying slides on the company's website. A replay of the webcast will be available for 30 days.
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
Apellis Pharmaceuticals, Inc. announced it will host a conference call and webcast on Tuesday, February 24, 2026, at 8:30 a.m. ET to discuss its financial results for the fourth quarter and full year 2025. Interested parties can pre-register for the call or access a live audio webcast and accompanying slides through the company’s website. Apellis Pharmaceuticals is a global biopharmaceutical company focused on complement science, with two C3-targeting medicines approved for four serious diseases, including geographic atrophy and rare kidney diseases.
Broad S&P Index Inclusion Might Change The Case For Investing In Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals (APLS) was recently added to several S&P indices, including the S&P 1000 and S&P 600, which is expected to raise its profile among institutional investors. While this broader index inclusion may enhance liquidity and shareholder base, the core investment case still depends on the commercial success of SYFOVRE and EMPAVELI and long-term safety. Investors are cautioned about the stock's high earnings multiples and ongoing ocular safety concerns, despite some fair value estimates suggesting potential undervaluation.
Broad S&P Index Inclusion Might Change The Case For Investing In Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals (APLS) was recently added to several S&P indices, including the S&P 1000 and S&P 600, which is likely to increase its visibility among institutional investors and index funds. While this inclusion broadens its potential investor base, the company's core investment case still depends on the commercial success and long-term safety of its products, SYFOVRE and EMPAVELI. Despite trading below some fair value estimates, Apellis screens as expensive on earnings multiples and has underperformed the market and its biotech peers.
A Look At Apellis Pharmaceuticals (APLS) Valuation After Recent S&P Index Additions
Apellis Pharmaceuticals (APLS) has been added to several S&P indices, influencing trading as index trackers rebalance. Despite recent stock volatility, with a 17.13% 90-day return contrasting with a 12.76% year-to-date decline, the company is considered undervalued at its current price of US$22.56 compared to an estimated fair value of $33.95. This undervaluation is supported by FDA label expansion for EMPAVELI into rare kidney diseases, though its high P/E ratio of 63.5x compared to industry averages raises questions about potential upside.
A Look At Apellis Pharmaceuticals (APLS) Valuation After Recent S&P Index Additions
Apellis Pharmaceuticals (APLS) has been added to several S&P indices, including the S&P 1000 and S&P 600, a move expected to influence trading as index trackers rebalance. Despite recent positive momentum in its share price (17.13% over 90 days), longer-term performance has been weaker, with a 1-year total shareholder return decline of 25.30%. The article discusses Apellis's valuation, noting it appears undervalued against analyst targets at US$22.56 compared to a narrative-driven fair value of $33.95, largely due to its expanding kidney and eye franchises, while also highlighting the challenge of its high P/E ratio of 63.5x compared to industry averages.
How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors
Apellis Pharmaceuticals has reported strong Q4 2025 revenue momentum for its complement inhibitor Empaveli, with preliminary U.S. net product revenue of approximately US$35.00 million. This growth reflects rapid adoption in treating paroxysmal nocturnal hemoglobinuria and other rare conditions, drawing investor attention to its commercial potential and current undervaluation. The article suggests that while recent momentum is positive, long-term success hinges on Empaveli's label expansion, SYFOVRE's uptake, and disciplined spending.
(APLS) Movement as an Input in Quant Signal Sets
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is showing divergent sentiment across different time horizons, suggesting choppy market conditions. Stock Traders Daily's AI models have generated three distinct trading strategies for APLS, including position trading, momentum breakout, and risk hedging strategies, with specific entry, target, and stop loss points. The analysis also provides multi-timeframe signal analysis with support and resistance levels for near-term, mid-term, and long-term outlooks.
How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors
Apellis Pharmaceuticals has reported strong momentum for its drug Empaveli, with preliminary Q4 2025 U.S. net product revenue of approximately US$35.00 million, indicating significant year-over-year growth and rapid adoption. This performance suggests promising market penetration and underappreciated commercial potential, reassuring investors about the company's complement franchise. The article highlights that while this reinforces short-term revenue, long-term success still hinges on continued label expansion, disciplined spending, and addressing concentration risks.
BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential
Bank of America upgraded Apellis Pharmaceuticals (APLS) to Buy from Neutral, maintaining a $28 price target. This decision is based on rapid adoption of Empaveli for rare kidney diseases, with 267 new patient forms since July approval, indicating strong commercial prospects. In contrast, Wells Fargo lowered its price target due to a slower-than-expected commercial ramp for Empaveli in other indications, though Syfovre estimates remain steady.
J. Safra Sarasin Holding AG Sells 45,184 Shares of Apellis Pharmaceuticals, Inc. $APLS
J. Safra Sarasin Holding AG has reduced its stake in Apellis Pharmaceuticals (NASDAQ:APLS) by 39.1%, selling 45,184 shares and now holding 70,500 shares valued at $1.595 million. This divestment comes as several insiders, including CFO Timothy Sullivan and Pascal Deschatelets, also sold shares in late January. Despite strong quarterly earnings that surpassed analyst estimates, the stock currently holds a "Hold" consensus rating with an average target price of $33.00.
Apellis Pharmaceuticals (NASDAQ:APLS) Upgraded to Hold at Barclays
Barclays has upgraded Apellis Pharmaceuticals (NASDAQ:APLS) to a "Hold" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst expectations with an EPS of $1.67 and revenue of $458.6 million, a 133% year-over-year increase. Despite mixed analyst coverage, the stock currently holds an average rating of "Hold" with a consensus price target of $33.00, and institutional investors own a significant portion of its shares.
BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential
Bank of America has upgraded Apellis Pharmaceuticals (APLS) to Buy with an unchanged price target of $28, citing underappreciated commercial prospects for their drug Empaveli in rare kidney diseases. This upgrade follows Empaveli's rapid adoption, securing 267 new patient start forms since its late July approval, achieving an initial 5% penetration of the US market. While Wells Fargo had lowered its price target due to a slower commercial ramp for Empaveli in other indications, BofA remains optimistic about future upside.
Apellis Turns GAAP Profitable As Syfovre Sales Shift Story To Execution
Apellis Pharmaceuticals (NasdaqGS: APLS) has achieved GAAP profitability, signaling a shift from a clinical-stage company to a commercial biotech driven by sales of its geographic atrophy treatment, Syfovre. This transition means the company's performance will now largely depend on the execution of its commercial strategy and demand for its product. Investors should monitor Syfovre's revenue, profit margins, and how Apellis balances reinvestment in its pipeline with cash flows from product sales.
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND) and Abivax SA Sponsored ADR (ABVX)
Healthcare sector analysts have provided updated ratings for Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND), and Abivax SA Sponsored ADR (ABVX). Apellis Pharmaceuticals received a Moderate Buy consensus with an average target of $34.00, Ascendis Pharma a Strong Buy with a $269.91 average target, and Abivax SA Sponsored ADR also a Strong Buy with a $153.88 average target. Specific analysts from Mizuho Securities, Morgan Stanley, and Truist Financial maintained their ratings on these companies.
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $28
BofA Securities analyst Tazeen Ahmad has maintained a "Buy" rating on Apellis Pharmaceuticals (APLS.US) and kept the target price at $28. According to TipRanks data, Ahmad has a 52.9% success rate and an average return of 2.6% over the past year. TipRanks provides independent analysis of financial analysts' recommendations, including success rates and average returns.
Apellis Turns GAAP Profitable As Syfovre Sales Shift Story To Execution
Apellis Pharmaceuticals has achieved GAAP profitability due to commercial sales of its geographic atrophy treatment, Syfovre. This marks a transition from a clinical-stage to a commercial-stage biotech, with performance now tied to product sales and execution. Investors should monitor Syfovre's revenue and profit margins, as well as the company's reinvestment in its pipeline.
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by EFG Asset Management North America Corp.
EFG Asset Management North America Corp. increased its holdings in Apellis Pharmaceuticals (NASDAQ:APLS) by 48% in the third quarter, bringing its total stake to 155,399 shares valued at $3.52 million. This comes despite significant insider selling, with the CEO and other insiders having sold over 125,000 shares in the last 90 days. Apellis Pharmaceuticals reported strong earnings, beating analyst expectations with an EPS of $1.67 and revenue of $458.6 million.
Is Apellis Pharmaceuticals (APLS) Now Attractive After Recent Share Price Weakness?
Apellis Pharmaceuticals (APLS) has experienced significant share price weakness, with declines over the past month and year. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 77.5%, with an intrinsic value of US$96.53 per share compared to its recent price of US$21.75. However, its Price/Earnings (P/E) ratio of 61.17x is higher than the industry average and Simply Wall St's "Fair Ratio" of 30.06x, indicating it is overvalued by this metric.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from Brokerages
Apellis Pharmaceuticals (NASDAQ:APLS) has received a "Moderate Buy" consensus from twenty analysts, with an average 1-year price target of $33.53 despite some recent price target trims by brokerages. The company reported strong Q3 earnings, beating analyst estimates, however, clustered insider selling totaling over $2.7 million has been noted. The article also details institutional investor activity and recent news impacting the stock, including an upgrade by BofA due to strong Empaveli uptake.
Apellis Pharma CEO Francois sells $592k in shares
Apellis Pharmaceuticals CEO Cedric Francois sold 27,192 shares of common stock for approximately $591,844 to cover tax withholding on Restricted Stock Units. Despite this sale, Francois maintains a significant stake in the company, directly owning 286,045 shares and beneficially owning more through trusts. The company reported strong financial performance with 42% revenue growth, although recent product revenue figures slightly missed analyst estimates, leading to mixed analyst ratings.
Nur Nicholson Sells 7,725 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock
Nur Nicholson, an insider at Apellis Pharmaceuticals (NASDAQ:APLS), sold 7,725 shares of the company's stock on January 22nd at an average price of $21.77, reducing her stake by 9.8%. This transaction, totaling approximately $168,173.25, followed other recent sales by Nicholson and clustered executive selling by other senior insiders. Despite a strong earnings report for the quarter, the stock has seen analyst price target reductions and is trading down, with a consensus "Moderate Buy" rating and a target price of $33.53.
Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel David Watson Sells 7,832 Shares
Apellis Pharmaceuticals General Counsel David Watson sold 7,832 shares of the company's stock for $170,502.64, reducing his stake by 8.13% to 88,531 shares. This transaction, along with other insider sales from senior executives, occurred between January 20-22 and was disclosed in an SEC filing. Despite these sales, Apellis recently reported strong Q4 2026 earnings, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" rating with a target price of $33.53.
Caroline Baumal Sells 2,797 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock
Caroline Baumal, an insider at Apellis Pharmaceuticals (NASDAQ:APLS), sold 2,797 shares of the company's stock on January 22nd at an average price of $21.77, reducing her stake by 3.13%. This sale follows another transaction on January 20th where she sold 1,882 shares. The article notes a pattern of clustered executive selling by multiple senior insiders, which may have negatively impacted short-term sentiment despite recent positive earnings and analyst upgrades from Bank of America.
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CAO Sells 2,064 Shares of Stock
Apellis Pharmaceuticals (NASDAQ:APLS) Chief Accounting Officer, James George Chopas, sold 2,064 shares of company stock on January 22nd, valued at approximately $44,933. This sale reduced his stake by 3.98%. The company recently reported strong quarterly earnings, beating analyst estimates, and holds a consensus "Moderate Buy" rating with an average price target of $33.53 despite recent insider selling from multiple senior executives.
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 5,928 Shares of Stock
Pascal Deschatelets, an insider at Apellis Pharmaceuticals (NASDAQ:APLS), sold 5,928 shares of the company's stock on January 22nd, reducing his stake by 0.51%. This sale was part of a larger pattern of clustered executive selling by several senior insiders between January 20th and 22nd, which likely negatively impacted investor sentiment. Despite the insider selling, Apellis Pharmaceuticals boasts a "Moderate Buy" consensus analyst rating with an average price target of $33.53, following a recent earnings beat and strong revenue growth.
Nicholson nur, Apellis Pharmaceuticals CTO, sells $43k in APLS stock
Nur Nicholson, CTO of Apellis Pharmaceuticals Inc (NASDAQ: APLS), sold 2,203 shares of company stock for $43,603 to cover tax obligations. This transaction followed the release of Restricted Stock Units. The article also notes recent financial reports for Apellis, including preliminary FY2025 product revenue and varied analyst ratings from firms like Goldman Sachs, BofA Securities, Cantor Fitzgerald, and Needham.
Apellis Valuation Ignores Empaveli Potential, Says Analyst
Bank of America Securities upgraded Apellis Pharmaceuticals to Buy, citing the significant commercial potential of its drug Empaveli for rare kidney diseases (C3G/IC‑MPGN), which is currently underappreciated in the company's valuation. Empaveli has shown promising early commercial performance and competitive advantages, leading BofA to increase its price forecast. Additionally, future catalysts like the Syfovre prefilled syringe are expected to further boost growth, despite previous challenges in its GA business.
Apellis Pharma CMO Baumal sells $37k in shares
Caroline Baumal, Chief Medical Officer of Apellis Pharmaceuticals Inc, sold 1,882 shares of common stock for $37,250 to cover tax withholding obligations. This transaction occurred amidst recent preliminary U.S. fiscal year 2025 product revenue announcements for Apellis, which fell slightly short of analyst estimates. The article also touches on recent analyst rating changes and price target adjustments for Apellis Pharmaceuticals from various firms.
Apellis Pharmaceuticals (NASDAQ:APLS) Upgraded at Bank of America
Bank of America upgraded Apellis Pharmaceuticals (NASDAQ:APLS) from "neutral" to "buy" with a $28 target price, indicating a 36.8% potential upside. This upgrade follows a strong earnings report where Apellis surpassed expectations with EPS of $1.67 and revenue of $458.6M, up 133% year-over-year. Despite recent insider stock sales, the company holds a consensus "Moderate Buy" rating from analysts with an average target of $33.53.
How Investors May Respond To Apellis Pharmaceuticals (APLS) Balancing EMPAVELI’s FDA Win With Slow Rare-Disease Uptake
Apellis Pharmaceuticals recently received FDA approval for EMPAVELI to treat rare kidney diseases, marking a significant regulatory win. However, the company faces challenges with slower-than-expected patient uptake for EMPAVELI and flat sales for SYFOVRE due to access and reimbursement issues. Investors are now focusing on the company's ability to boost commercial traction, address market hurdles, and improve its near-term profitability despite the scientific success.
Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $26,399.86 in Stock
Apellis Pharmaceuticals (NASDAQ:APLS) insider Mark Jeffrey Delong sold 1,334 shares of the company's stock valued at $26,399.86 on January 20th, reducing his stake by 1.61%. This sale, along with others by the CFO and General Counsel, can be viewed negatively by investors, despite the company reporting strong quarterly results and analysts maintaining a "Moderate Buy" rating with an average price target of $33.53. The stock is currently trading below its 50- and 200-day moving averages.
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 1,882 Shares of Stock
Apellis Pharmaceuticals (NASDAQ:APLS) director Caroline Baumal sold 1,882 shares of the company's stock for approximately $37,245. This sale, along with others by the CFO and General Counsel, reduced Baumal's stake by 2.06%. Despite the insider selling, Apellis reported strong quarterly earnings, beating analyst estimates, and has a consensus "Moderate Buy" rating from analysts with an average target price of $33.53.
How Investors May Respond To Apellis Pharmaceuticals (APLS) Balancing EMPAVELI’s FDA Win With Slow Rare-Disease Uptake
Apellis Pharmaceuticals recently received FDA approval for EMPAVELI to treat rare kidney diseases C3 glomerulopathy and IC-MPGN, making it the first approved therapy for these conditions. Despite this regulatory win, the company faces challenges with slow patient uptake for EMPAVELI and flat sales for SYFOVRE due to access and reimbursement issues. This situation creates a tension between scientific success and the practicalities of rare-disease drug launches, prompting investors to focus on the company's ability to convert regulatory success into commercial traction and address market barriers.
Bank of America Upgrades Apellis Pharmaceuticals to Buy, Highlights Strong Empaveli Launch
Bank of America has upgraded Apellis Pharmaceuticals (APLS) to a "Buy" rating, maintaining a $28 price target, due to the strong commercial potential and launch trajectory of its drug Empaveli. Since its FDA approval in July, Empaveli has garnered 267 new patient start forms, indicating significant market acceptance and rapid penetration, especially given its superior efficacy compared to competitors. Despite some analysts lowering price targets due to slower-than-expected ramps, the firm is optimistic about its growth potential in new kidney disease indications and international markets following EU approval.
Why Is Apellis Pharma Stock Gaining Wednesday? - Apellis Pharmaceuticals (NASDAQ:APLS)
Apellis Pharmaceuticals (NASDAQ: APLS) is experiencing increased stock value following an upgrade from Bank of America Securities. The upgrade is attributed to the strong early commercial performance and underappreciated potential of its drug Empaveli in treating rare kidney diseases, specifically C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Additionally, future catalysts like the approval of a prefilled syringe for Syfovre are expected to further boost the company's market position and revenue outlook.
Liquidity Mapping Around (APLS) Price Events
This article from Stock Traders Daily discusses Apellis Pharmaceuticals Inc. (APLS) price events, highlighting weak near and mid-term sentiment but a neutral long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional short setup. The piece details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis for support and resistance levels.
Wells Fargo Maintains Overweight Rating for APLS, Lowers Price T
Wells Fargo has reiterated its "Overweight" rating for Apellis Pharmaceuticals (APLS) but has lowered its price target from $29.00 to $26.00, a 10.34% decrease. This adjustment follows similar price target reductions by other analysts due to ongoing assessments of the company's performance and market conditions. Despite the lowered targets, the average one-year price target from 19 analysts suggests a potential upside of 74.74% from the current price, with GuruFocus estimating an even higher upside based on its fair value calculations.
